Butoconazolum [INN-Latin] en es it fr

Butoconazolum [INN-Latin] Brand names, Butoconazolum [INN-Latin] Analogs

Butoconazolum [INN-Latin] Brand Names Mixture

  • No information avaliable

Butoconazolum [INN-Latin] Chemical_Formula


Butoconazolum [INN-Latin] RX_link


Butoconazolum [INN-Latin] fda sheet

Butoconazolum_[INN-Latin] FDA

Butoconazolum [INN-Latin] msds (material safety sheet)

Butoconazolum_[INN-Latin] MSDS

Butoconazolum [INN-Latin] Synthesis Reference

No information avaliable

Butoconazolum [INN-Latin] Molecular Weight

411.776 g/mol

Butoconazolum [INN-Latin] Melting Point

Melts at about 159°C with decomposition (nitrate salt)

Butoconazolum [INN-Latin] H2O Solubility

Nitrate salt: 0.26 mg/ml (practically insoluble)

Butoconazolum [INN-Latin] State


Butoconazolum [INN-Latin] LogP


Butoconazolum [INN-Latin] Dosage Forms

Vaginal cream (2%)

Butoconazolum [INN-Latin] Indication

For the local treatment of vulvovaginal candidiasis (infections caused by Candida)

Butoconazolum [INN-Latin] Pharmacology

Butoconazole is an imidazole derivative that has fungicidal activity in vitro against Candida spp. and has been demonstrated to be clinically effective against vaginal infections due to Candida albicans. Candida albicans has been identified as the predominant species responsible for vulvovaginal candidasis.

Butoconazolum [INN-Latin] Absorption

Following vaginal administration of butoconazole nitrate vaginal cream, 2% to 3 women, 1.7% (range 1.3-2.2%) of the dose was absorbed on average.

Butoconazolum [INN-Latin] side effects and Toxicity

Oral, rat: LD50 = >1720 mg/kg.

Butoconazolum [INN-Latin] Patient Information

Butoconazolum [INN-Latin] Organisms Affected

Fungi, yeast and protozoans